Chemoresistance in pancreatic cancer: Emerging concepts (Review)

Oncology Letters

Volumn 13, Issue 4, 2017, Pages 2507-2513

  Gnanamony, Manu ^a   Gondi, Christopher S ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Cancer stem cells; Chemoresistance; Gemcitabine; Pancreatic cancer; Tumor microenvironment

Indexed keywords

ACETYLSALICYLIC ACID; ALDEHYDE DEHYDROGENASE ISOENZYME 1; ARSENITE SODIUM; CENTCHROMAN; CURAXIN; CYCLIN B1; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; FOCAL ADHESION KINASE; FOLINIC ACID; GEMCITABINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; I KAPPA B; IRINOTECAN; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; MUCIN 1; NUCLEOSIDE TRANSPORTER; OXALIPLATIN; PACLITAXEL; PROTEIN P53; PROTEIN TYROSINE KINASE; QUINAZOLINE DERIVATIVE; SEPANTRONIUM BROMIDE; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR ZEB1; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR;

ADJUVANT THERAPY; APOPTOSIS; CANCER RESISTANCE; CANCER STAGING; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HYPOXIA; PANCREAS CANCER; PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PROTEIN EXPRESSION; REVIEW; SURVIVAL RATE; TUMOR MICROENVIRONMENT; WNT SIGNALING PATHWAY;

EID: 85015300732     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2017.5777     Document Type: Review

References (60)

1. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM and Matrisian LM: Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver and pancreas cancers in the united states. Cancer Res 74: 2913-2921, 2014.
2. Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin 65: 5-29, 2015.
3. Carmichael J, Fink U, Russell RC, Spittle MF, Harris AL, Spiessi G and Blatter J: Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 73: 101-105, 1996.
4. Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15: 2403-2413, 1997.
5. Garrido-Laguna I and Hidalgo M: Pancreatic cancer: From state-of-the-art treatments to promising novel therapies. Nat Rev Clin Oncol 12: 319-334, 2015.
6. Rossi ML, Rehman AA and Gondi CS: Therapeutic options for the management of pancreatic cancer. World J Gastroenterol 20: 11142-11159, 2014.
7. de Sousa Cavalcante L and Monteiro G: Gemcitabine: Metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer. Eur J Pharmacol 741: 8-16, 2014.
8. Huang P, Chubb S, Hertel LW, Grindey GB and Plunkett W: Action of 2',2'-difluorodeoxycytidine on DNA synthesis. Cancer Res 51: 6110-6117, 1991.
9. Fiorini C, Cordani M, Padroni C, Blandino G, Di Agostino S and Donadelli M: Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine. Biochim Biophys Acta 1853: 89-100, 2015.
10. κB loop on epithelial-mesenchymal transition and chemoresistance induced by hypoxia in pancreatic cancer cells. Oncol Rep 31: 1891-1898, 2014.
11. Maftouh M, Avan A, Sciarrillo R, Granchi C, Leon LG, Rani R, Funel N, Smid K, Honeywell R, Boggi U, et al: Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia. Br J Cancer 110: 172-182, 2014.
12. Ono H, Basson MD and Ito H: PTK6 potentiates gemcitabine-induced apoptosis by prolonging S-phase and enhancing DNA damage in pancreatic cancer. Mol Cancer Res 13: 1174-1184, 2015.
13. Bhattacharjee V, Zhou Y and Yen TJ: A synthetic lethal screen identifies the vitamin D receptor as a novel gemcitabine sensitizer in pancreatic cancer cells. Cell Cycle 13: 3839-3856, 2014.
14. Tréhoux S, Duchêne B, Jonckheere N and Van Seuningen I: The MUC1 oncomucin regulates pancreatic cancer cell biological properties and chemoresistance. Implication of p42-44 MAPK, akt, bcl-2 and MMP13 pathways. Biochem Biophys Res Commun 456: 757-762, 2015.
15. Khan S, Ebeling MC, Chauhan N, Thompson PA, Gara RK, Ganju A, Yallapu MM, Behrman SW, Zhao H, Zafar N, et al: Ormeloxifene suppresses desmoplasia and enhances sensitivity of gemcitabine in pancreatic cancer. Cancer Res 75: 2292-2304, 2015.
16. Yang MH, Lee KT, Yang S, Lee JK, Lee KH and Rhee JC: KML001 enhances anticancer activity of gemcitabine against pancreatic cancer cells. Anticancer Res 35: 183-189, 2015.
17. Pathania D, Kuang Y, Sechi M and Neamati N: Mechanisms underlying the cytotoxicity of a novel quinazolinedione-based redox modulator, QD232, in pancreatic cancer cells. Br J Pharmacol 172: 50-63, 2015.
18. Zhang Y, Liu L, Fan P, Bauer N, Gladkich J, Ryschich E, Bazhin AV, Giese NA, Strobel O, Hackert T, et al: Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer. Oncotarget 6: 9999-10015, 2015.
19. Burkhart C, Fleyshman D, Kohrn R, Commane M, Garrigan J, Kurbatov V, Toshkov I, Ramachandran R, Martello L and Gurova KV: Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer. Oncotarget 5: 11038-11053, 2014.
20. Zhao X, Puszyk WM, Lu Z, Ostrov DA, George TJ, Robertson KD and Liu C: Small molecule inhibitor YM155-mediated activation of death receptor 5 is crucial for chemotherapy-induced apoptosis in pancreatic carcinoma. Mol Cancer Ther 14: 80-89, 2015.
21. Huang YT, Cheng CC, Lin TC, Chiu TH and Lai PC: Therapeutic potential of sepantronium bromide YM155 in gemcitabine-resistant human urothelial carcinoma cells. Oncol Rep 31: 771-780, 2014.
22. Yoon DH, Shin JS, Jin DH, Hong SW, Jung KA, Kim SM, Hong YS, Kim KP, Lee JL, Suh C, et al: The survivin suppressant YM155 potentiates chemosensitivity to gemcitabine in the human pancreatic cancer cell line MiaPaCa-2. Anticancer Res 32: 1681-1688, 2012.
23. Suzuki S, Okada M, Shibuya K, Seino M, Sato A, Takeda H, Seino S, Yoshioka T and Kitanaka C: JNK suppression of chemotherapeutic agents-induced ROS confers chemoresistance on pancreatic cancer stem cells. Oncotarget 6: 458-470, 2015.
24. Ilmer M, Boiles AR, Regel I, Yokoi K, Michalski CW, Wistuba II, Rodriguez J, Alt E and Vykoukal J: RSPO2 enhances canonical wnt signaling to confer stemness-associated traits to susceptible pancreatic cancer cells. Cancer Res 75: 1883-1896, 2015.
25. Herreros-Villanueva M, Er TK and Bujanda L: Retinoic acid reduces stem cell-like features in pancreatic cancer cells. Pancreas 44: 918-924, 2015.
26. Hoshino Y, Nishida J, Katsuno Y, Koinuma D, Aoki T, Kokudo N, Miyazono K and Ehata S: Smad4 decreases the population of pancreatic cancer-initiating cells through transcriptional repression of ALDH1A1. Am J Pathol 185: 1457-1470, 2015.
27. Cioffi M, Trabulo S, Hidalgo M, Costello E, Greenhalf W, Erkan M, Kleeff J, Sainz B Jr and Heeschen C: Inhibition of CD47 effectively targets pancreatic cancer stem cells via dual mechanisms. Clin Cancer Res 21: 2325-2337, 2015.
28. Ma C, Ding Y, Yu W, Wang Q, Meng B and Huang T: microRNA-200c overexpression plays an inhibitory role in human pancreatic cancer stem cells by regulating epithelial-mesenchymal transition. Minerva Med 106: 193-202, 2015.
29. Meidhof S, Brabletz S, Lehmann W, Preca BT, Mock K, Ruh M, Schüler J, Berthold M, Weber A, Burk U, et al: ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat. EMBO Mol Med 7: 831-847, 2015.
30. Jiao F, Hu H, Han T, Yuan C, Wang L, Jin Z, Guo Z and Wang L: Long noncoding RNA MALAT-1 enhances stem cell-like phenotypes in pancreatic cancer cells. Int J Mol Sci 16: 6677-6693, 2015.
31. Zhao Y, Zhao L, Ischenko I, Bao Q, Schwarz B, Nieß H, Wang Y, Renner A, Mysliwietz J, Jauch KW, et al: Antisense inhibition of microRNA-21 and microRNA-221 in tumor-initiating stem-like cells modulates tumorigenesis, metastasis, and chemotherapy resistance in pancreatic cancer. Target Oncol 10: 535-548, 2015.
32. Moir JA, Mann J and White SA: The role of pancreatic stellate cells in pancreatic cancer. Surg Oncol 24: 232-238, 2015.
33. Schober M, Jesenofsky R, Faissner R, Weidenauer C, Hagmann W, Michl P, Heuchel RL, Haas SL and Löhr JM: Desmoplasia and chemoresistance in pancreatic cancer. Cancers (Basel) 6: 2137-2154, 2014.
34. Rhim AD, Oberstein PE, Thomas DH, Mirek ET, Palermo CF, Sastra SA, Dekleva EN, Saunders T, Becerra CP, Tattersall IW, et al: Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 25: 735-747, 2014.
35. Özdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, Laklai H, Sugimoto H, Kahlert C, Novitskiy SV, et al: Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25: 719-734, 2014.
36. Duluc C, Moatassim-Billah S, Chalabi-Dchar M, et al.: Pharmacological targeting of the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumour chemoresistance. EMBO Mol Med 7: 735-53, 2015.
37. Cao F, Li J, Sun H, Liu S, Cui Y and Li F: HES 1 is essential for chemoresistance induced by stellate cells and is associated with poor prognosis in pancreatic cancer. Oncol Rep 33: 1883-1889, 2015.
38. α signaling mediates the effects of PSCs on GEM chemoresistance through an IL-6 autocrine loop in pancreatic cancer cells. Oncotarget 6: 3085-3097, 2015.
39. Sherman MH, Yu RT, Engle DD, Ding N, Atkins AR, Tiriac H, Collisson EA, Connor F, Van Dyke T, Kozlov S, et al: Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell 159: 80-93, 2014.
40. Kwon JJ, Nabinger SC, Vega Z, Sahu SS, Alluri RK, Abdul-Sater Z, Yu Z, Gore J, Nalepa G, Saxena R, et al: Pathophysiological role of microRNA-29 in pancreatic cancer stroma. Sci Rep 5: 11450, 2015.
41. Sainz B Jr, Alcala S, Garcia E, Sanchez-Ripoll Y, Azevedo MM, Cioffi M, Tatari M, Miranda-Lorenzo I, Hidalgo M, Gomez-Lopez G, et al: Microenvironmental hCAP-18/LL-37 promotes pancreatic ductal adenocarcinoma by activating its cancer stem cell compartment. Gut 64: 1921-1935, 2015.
42. Amit M and Gil Z: Macrophages increase the resistance of pancreatic adenocarcinoma cells to gemcitabine by upregulating cytidine deaminase. Oncoimmunology 2: e27231, 2013.
43. Sainz B Jr, Martín B, Tatari M, Heeschen C and Guerra S: ISG15 is a critical microenvironmental factor for pancreatic cancer stem cells. Cancer Res 74: 7309-7320, 2014.
44. Xu J, Wang T, Cao Z, Huang H, Li J, Liu W, Liu S, You L, Zhou L, Zhang T and Zhao Y: MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis. Oncotarget 5: 6983-6993, 2014.
45. Liang C, Yu XJ, Guo XZ, Sun MH, Wang Z, Song Y, Ni QX, Li HY, Mukaida N and Li YY: MicroRNA-33amediated downregulation of pim-3 kinase expression renders human pancreatic cancer cells sensitivity to gemcitabine. Oncotarget 6: 14440-14445, 2015.
46. Trehoux S, Lahdaoui F, Delpu Y, Renaud F, Leteurtre E, Torrisani J, Jonckheere N and Van Seuningen I: Micro-RNAs miR-29a and miR-330-5p function as tumor suppressors by targeting the MUC1 mucin in pancreatic cancer cells. Biochim Biophys Acta 1853: 2392-2403, 2015.
47. α is a microRNA target and affects chemosensitivity in pancreatic cancer. J Surg Res 196: 285-293, 2015.
48. Hasegawa S, Eguchi H, Nagano H, Konno M, Tomimaru Y, Wada H, Hama N, Kawamoto K, Kobayashi S, Nishida N, et al: MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer. Br J Cancer 111: 1572-1580, 2014.
49. Xu Q, Li P, Chen X, Zong L, Jiang Z, Nan L, Lei J, Duan W, Zhang D, Li X, et al: miR-221/222 induces pancreatic cancer progression through the regulation of matrix metalloproteinases. Oncotarget 6: 14153-14164, 2015.
50. Cioffi M, Trabulo SM, Sanchez-Ripoll Y, Miranda-Lorenzo I, Lonardo E, Dorado J, Reis Vieira C, Ramirez JC, Hidalgo M, Aicher A, et al: The miR-17-92 cluster counteracts quiescence and chemoresistance in a distinct subpopulation of pancreatic cancer stem cells. Gut 64: 1936-1948, 2015.
51. Migault M, DonnouFournet E, Galibert MD and Gilot D: Definition and identification of small RNA sponges: Focus on miRNA sequestration. Methods pii: S1046-2023 30221-3, 2016.
52. Li TR, Jia YJ, Wang Q, Shao XQ and Lv RJ: Circular RNA: A new star in neurological diseases. Int J Neurosci 1-9, 2016 (Epub ahead of print).
53. Qu S, Zhong Y, Shang R, Zhang X, Song W, Kjems J and Li H: The emerging landscape of circular RNA in life processes. RNA Biol 1-8, 2016 (Epub ahead of print).
54. Meng X, Li X, Zhang P, Wang J, Zhou Y and Chen M: Circular RNA: An emerging key player in RNA world. Brief Bioinform pii: bbw045: 2016 (Epub ahead of print).
55. Huarte M and Rinn JL: Large non-coding RNAs: Missing links in cancer? Hum Mol Genet 19: R152-R161, 2010.
56. Müller S, Raulefs S, Bruns P, Afonso-Grunz F, Plötner A, Thermann R, Jäger C, Schlitter AM, Kong B, Regel I, et al: Next-generation sequencing reveals novel differentially regulated mRNAs, lncRNAs, miRNAs, sdRNAs, and a piRNA in pancreatic cancer. Mol Cancer 14: 94, 2015.
57. Li Z, Zhao X, Zhou Y, Liu Y, Zhou Q, Ye H, Wang Y, Zeng J, Song Y, Gao W, et al: The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer. J Transl Med 13: 84, 2015.
58. Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK and Kjems J: Natural RNA circles function as efficient microRNA sponges. Nature 495: 384-388, 2013.
59. β-catenin pathway. Oncotarget 6: 6001-6013, 2015.
60. Enuka Y, Lauriola M, Feldman ME, Sas-Chen A, Ulitsky I and Yarden Y: Circular RNAs are long-lived and display only minimal early alterations in response to a growth factor. Nucleic Acids Res 44: 1370-1383, 2016.